As CRISPR targeting COX4I1 increased the sensitivity of AML cells to venetoclax (Figure 6), we further sought to investigate the capacity of chlorpromazine to potentiate the anti‐leukemia effects of venetoclax. The gene discussed is COX4I1; the disease is acute myeloid leukemia.